Evidence-based nutrition in gastrointestinal fistulae and short bowel syndrome;Nutrición basada en la evidencia en las fístulas digestivas el intestino corto

Endocrinologia y Nutricion

Volumn 52, Issue SUPPL. 2, 2005, Pages 83-90

  Vega Pinero B ^a   Penalver Talavera D ^a   Fernandez Estivariz C ^b  

^a HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Enteral nutrition; Enterocutaneous fistulae; Gastrointestinal fistulae; Glucagon like peptide 2; Glutamine; Growth hormone; Octreotide; Parenteral nutrition; Short bowel; Somatostatin

Indexed keywords

GLUCAGON LIKE PEPTIDE 2; GLUTAMINE; GROWTH HORMONE; OCTREOTIDE; SOMATOSTATIN;

ARTIFICIAL FEEDING; DIGESTIVE SYSTEM FISTULA; DISEASE COURSE; ENTERIC FEEDING; EVIDENCE BASED MEDICINE; HUMAN; NUTRITIONAL ASSESSMENT; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PARENTERAL NUTRITION; REVIEW; SHORT BOWEL SYNDROME;

EID: 34547666128     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/S1575-0922(05)74658-1     Document Type: Article

References (50)

1. Evidence Based Medicine Working Group. La medicina basada en la evidencia: guías del usuario de la bibliografía médica. JAMA (ed. esp) 1997.
2. Del Olmo D, Konning MA, López T, Alcázar V, Martínez de Icaya P, Vázquez C. Utilización de las fórmulas especiales de Nutrición enteral: recomendaciones basadas en la evidencia. Endocrinol Nutr. 2002;49 Supl 2:9-14.
3. Canadian Task Force on the Periodic Health Examination. The periodic health examination. J Can Med Assoc. 1979;121:1193-254.
4. Berry SM, Fischer JE. Classification and pathophysiology of enterocutaneous fistulas. Surg Clin North Am. 1996;76:1009-18.
5. Falconi M, Pederzoli P. The relevance of gastrointestinal fistulae in clinical practice: a review. Gut. 2002;49 Suppl 4:2-10.
6. Fukuchi S, Seeburger J, Parquet G, Rolandelli R. Nutrition support of patients with enterocutaneous fistulas. Nutr Clin Pract. 1998;13:59-65.
7. Foster CE, Lefor AT. General management or gastrointestinal fistulas. Surg Clin North Am. 1996;76:1019-33.
8. ASPEN Board of Directors and the Clinical Guidelines Task Force. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. Gastrointestinal fistulae. JPEN. 2002;26 Suppl 1:76SA-8.
9. Ryan JA, Adye BA, Weinstein AJ. Enteric fistulas. En: Rombeau JL, Caldwell MD, editors. Clinical nutrition. Vol II. Parenteral nutrition. Philadelphia: WB Saunders; 1986. p. 419-36.
10. Himal HS, Allard JR, Nadea JE. The importance of adequate nutrition in closure of small intestine fistulas. Br J Surg. 1974;61:724-30.
11. Deitel M. Nutritional management of external gastrointestinal fistulas. Can J Surg. 1976;19:505-9.
12. Meguid MM, Campos ACL. Nutritional management of patients with gastrointestinal fistulas. Surg Clin North Am. 1996;76:1035-80.
13. Arenas-Márquez H, Anaya-Prado R, Hurtado H, Fernández J, Galindo-Mendoza L, Terrazas-Espitia F, et al. Conference review: Mexican consensus on the integral management of digestive tract fistulas. Nutrition. 1999;15:235-8.
14. Makhdoom ZA, Komar MJ, Still CD. Nutrition and enterocutaneous fistulas. J Clin Gastroenterol. 2000;31:195-204.
15. Hesse U, Ysebaert D, De Hemptinne B. Role of somatostatin-14 and its analogues in the management of gastrointestinal fistulae: clinical data. Gut. 2002; Suppl 4:11-20.
16. Torres AJ, Landa JI, Moreno-Azcoitia M, Argüello JM, Silecchia G, Castro J, et al. Somatostatin in the management of gastrointestinal fistulas. A multicenter trial. Arch Surg. 1992;127:97-9.
17. Sancho JJ, Di Constanzo J, Nubiola P, Beguiristain A, Roqueta F, Franch G, et al. Randomized double-blind placebo-controlled trial of early octreotide in patients with postoperative enterocutaneous fistula. Br J Surg. 1995;85:638-41.
18. Hernández-Aranda JC, Gallo-Chico B, Flores-Ramírez LA, Avalos-Huante R, Magos-Vázquez FJ, Ramírez-Barba EJ. Tratamiento de las fístulas enterocutáneas con o sin octreótida y nutrición parenteral. Nutr Hosp. 1996;11:226-9.
19. Jamil M, Ahmed U, Sobia H. Role of somatostatin analogues in the management of enterocutanoeous fistulae. J Coll Physicians Surg Pak. 2004;14:237-40.
20. ASPEN Board of Directors and the Clinical Guidelines Task Force. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. Short-bowel syndrome. J Parenteral Enteral Nutr. 2002;26 Suppl 1:70-3.
21. Scolapio JS. Current update of short-bowel syndrome. Curr Opin Gastroenterol. 2004;20:143-5.
22. Jeppesen PB, Mortensen PB. Experimental approaches: dietary and hormone therapy. Best Pract Res Clin Gastroenterol. 2003;17:1041-54.
23. Thomson ABR, Keelan M, Thiesen A, Clandinin MT, Ropeleski M, Wild GE. Small bowel review. Normal physiology part 1. Dig Dis Sci. 2001;46:2567-87.
24. Thomson ABR, Keelan M, Thiesen A, Clandinin MT, Ropeleski M, Wild GE. Small bowel review. Normal physiology, (II). Dig Dis Sci. 2001;46:2588-607.
25. Nightingale JM, Kamm MA, Van der Sijp JR, Ghatei MA, Bloom SR, Lennard-Jones JE. Gastrointestinal hormones in short bowel syndrome. Peptide YY may be the "colonic brake" to gastric emptying. Gut. 1996;39:267-72.
26. Nightingale JM, Walker ER, Farthing MJ, Lennard-Jones JE. Effect of omeprazole on intestinal output in the short bowel syndrome. Aliment Pharmacol Therap. 1991;5:405-12.
27. Cortot A, Fleming CR, Malagelada JR. Improved nutrient absorption after cimetidine in short bowel syndrome with gastric hypersecretion. N Engl J Med. 1979;300:79-80.
28. Nightingale JMD, Lennard-Jones JE. The short bowel syndrome. What's new and old? Dig Dis. 1993;11:12-31.
29. Scolapio JS. Treatment of short-bowel syndrome. Curr Opin Clin Nutr Metab Care. 2001;4:557-60.
30. Wilmore DW. Indications for specific therapy in the rehabilitation of patients with the short-bowel syndrome. Best Pract Res Clin Gastroenterol. 2003;17:895-906.
31. Ksiazyk J, Piena M, Kierkus J, Lyszkowska M. Hydrolyzed versus nonhydrolyzed protein diet in short bowel syndrome in children. J Pediatr Gastroenterol Nutr. 2002;35:615-8.
32. Vázquez C. Nuevos nutrientes en nutrición enteral. Nutr Hosp. 2000;15:69-74.
33. Gardemann A, Watanabe Y, Grosse V, Hesse S, Jungermann K. Increase in intestinal glucose absorption and hepatic glucose uptake elicited by luminal but not vascular glutamine in the jointly perfused small intestine and liver in the rat. Biochem J. 1992;283:759-65.
34. Beaugerie L, Carbonnel F, Hecketsweiler B, Dechelotte P, Gendre JP, Cosnes J. Effects of an isotonic oral rehydratation solution, enriched with glutamine, on fluid and sodium absorption in patients with a short-bowel. Aliment Pharmacol Ther. 1997;11:741-6.
35. Scolapio JS, McGreevy K, Tennyson GS, Burnett OL. Effect of glutamine in short-bowel syndrome. Clin Nutr. 2001;20:319-23.
36. Benhamou PH, Canarelli JP, Richard S, Cordonier C, Postel JP, Grenier E, et al. Human recombinant growth hormone increases small bowel lengthening after massive small bowel resection in piglets. J Pediatr Surg. 1997;32:1332-6.
37. Ellegard L, Bosaeus I, Nordgren S, Bengtsson BA. Low-dose recombinant human growth hormone increases body weight and lean body mass in patients with short bowel syndrome. Ann Surg. 1997;225:88-96.
38. Ellegard E, Ellegard L. Nasal airflow in growth hormone treatment. Rhinology. 1998;36:66-8.
39. Seguy D, Vahedi K, Kapel N, Souberbielle JC, Messing B. Low-dose growth hormone in adult home parenteral nutrition-dependent short bowel syndrome patients. A positive study. Gastroenterology. 2003;124:293-302.
40. Byrne TA, Morrissey TB, Nattakom TV, Ziegler TR, Wilmore DW. Growth hormone, glutamine, and a modified diet enhance nutrient absorption in patients with severe short bowel syndrome. J Parenteral Enteral Nutr. 1995;19:296-302.
41. Byrne TA, Persinger RL, Young LS, Ziegler TR, Wilmore DW. A new treatment for patients with short-bowel syndrome. Growth hormone, glutamine, and a modified diet. Ann Surgery. 1995;222:243-54.
42. Scolapio JS, Camilleri M, Fleming CR, Oenning LV, Burton DD, Sebo TJ, et al. Effect of growth hormone, glutamine, and diet on adaptation in short-bowel syndrome: a randomised, controlled study. Gastroenterology. 1997;113:1074-81.
43. Scolapio JS. Effect of growth hormone, glutamine, and diet on body composition in short bowel syndrome: a randomised, controlled study. J Parenteral Enteral Nutr. 1999;23:309-13.
44. Szkudlarek J, Jeppesen PB, Mortensen PB. Effect of high dose growth hormone with glutamine and no change in diet on intestinal absorption in short bowel patients: a randomised, double blind, crossover, placebo controlled study. Gut. 2000;47:199-205.
45. Jeppesen PB, Szkudlarek J, Mortensen PB. Effect of high-dose growth hormone and glutamine on body composition, urine creatinine excretion, fatty acid absorption, and essential fatty acids status in short bowel patients: a randomised, double-bind, crossover, placebo-controlled study. Scand J Gastroenterol. 2001;36:48-54.
46. Wilmore DW, Lacey JM, Soultanakis RP, Bosch RL, Byrne TA. Factors predicting a successful outcome after pharmacologic bowel compensation. Ann Surg. 1997;226:288-93.
47. Wu GH, Wu ZH, Wu ZG. Effects of bowel rehabilitation and combined trophic therapy on intestinal adaptation in short bowel patients. World J Gastroenterol. 2003;9:2601-4.
48. Jeppesen PB, Hartmann B, Thulesen J, Graff J, Lohmann J, Hansen BS, et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology. 2001;120:1041-3.
49. Haderslev KV, Jeppesen PB, Hartmann B, Thulesen J, Sorensen HA, Graff J, et al. Short-term administration of glucagons-like peptide-2. Effects on bone mineral density and markers of bone turnover in short-bowel patients with no colon. Scand J Gastroenterol. 2002;37:392-8.
50. Matarese LE, Seidner DL, Steiger E. Growth hormone, glutamine, and modified diet for intestinal adaptation: a systematic review of the literature. J Am Diet Assoc. 2004;104:1265-72.